Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
This study has been completed.
Study NCT00992069   Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

First Received on October 1, 2009.   Last Updated on April 1, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Tuberculosis
HIV
More general conditions related to this trial
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections
Interventions listed in this trial
Efavirenz (EFV)
TMC207
Additional drug interventions recognized in this trial
Efavirenz
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services